Opdivo NSCLC failure opens door for other PD-1s

The failure of PD-1 inhibitor Opdivo nivolumab in a first-line non-small cell lung cancer trial could afford sponsors of other PD-1 mAbs an opportunity to gain market share despite lagging behind the drugs that currently dominate the PD-1 category.

According to ClinicalTrials.gov, data are due next year from the initial first-line Phase III NSCLC studies of Tecentriq atezolizumab ( MPDL3280A) from Roche (SIX:ROG; OTCQX:RHHBY); durvalumab ( MEDI4736) from AstraZeneca plc (LSE:AZN; NYSE:AZN); and avelumab ( MSB0010718C) from Merck KGaA (Xetra:MRK) and partner Pfizer Inc. (NYSE:PFE). ...